Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141906 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02141906 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT02141906, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a pilot study of Onconzene Microspheres for intra-arterial delivery of doxorubicin for the treatement of patients with unresectable hepatocellular cancer.
Interventions
- OTHER Oncozene-DEB-TACE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-01-21 |
| Est. Completion | 2022-05-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02141906
The ClinicalTrials.gov registry entry for NCT02141906 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oncozene-DEB-TACE is the first listed.
NCT02141906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02141906 about?
NCT02141906 is a clinical study titled "A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin". This is a pilot study of Onconzene Microspheres for intra-arterial delivery of doxorubicin for the treatement of patients with unresectable hepatocellular cancer.
What is the current status of trial NCT02141906?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2015-01-21. Estimated completion is 2022-05-16.
What interventions are being tested in trial NCT02141906?
The interventions under investigation include: Oncozene-DEB-TACE (OTHER).
Who is sponsoring clinical trial NCT02141906?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.